$17.50
-1.16 (-6.22%)
Open$18.23
Previous Close$18.66
Day High$18.92
Day Low$17.21
52W High$45.50
52W Low$4.97
Volume—
Avg Volume123.6K
Market Cap132.50M
P/E Ratio—
EPS$-26.99
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
-10.0% upside
Current
$17.50
$17.50
Target
$15.75
$15.75
$10.91
$15.75 avg
$18.65
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 61.54M | 17.68M | 17.52M |
| Net Income | -59,603,671 | -69,679,191 | -1,532,650 |
| Profit Margin | -96.9% | -416.1% | -8.8% |
| EBITDA | -58,738,476 | -74,344,734 | -1,913,244 |
| Free Cash Flow | — | — | -1,533,941 |
| Rev Growth | +180.1% | -14.7% | +0.6% |
| Debt/Equity | — | 0.25 | 1.52 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |